Health
Biomarkers that are predictive of clinical benefit in Trop-2-expressing triple-negative breast cancer – News-Medical.Net
Oncotarget recently published “Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer” which reported that…
Reviewed by Emily Henderson, B.Sc.Nov 3 2020
Oncotarget recently published “Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer” which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.
Further, two Trop-2-transfectants of MDA-MB-231, C13, and C39, were treated in mice with SG to…
-
Business23 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News23 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General17 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General22 hours agoOlder Aussies back increased superannuation tax